Related Experiment Video

Updated: Jun 8, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

The Far Side of Resistance to RAS Inhibitors

Michelangelo Marasco1, Sandra Misale2

  • 1Catholic University of the Sacred Heart and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.

Cancer Discovery
|November 1, 2024
PubMed

Insights

Nongenetic mechanisms and cell plasticity are key to resistance against RAS inhibitors in pancreatic cancer and lung cancer. Understanding these factors is crucial for developing effective cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • RAS inhibitors are a critical class of targeted therapies for cancers driven by RAS mutations.
  • Resistance to RAS inhibitors remains a significant clinical challenge, limiting treatment efficacy.
  • Nongenetic mechanisms and cell plasticity are increasingly recognized as drivers of therapeutic resistance.

Purpose of the Study:

  • To highlight the critical role of nongenetic mechanisms in mediating resistance to RAS inhibitors.
  • To explore the contribution of cell plasticity to acquired resistance in pancreatic ductal adenocarcinoma and non-small cell lung cancer.
  • To provide insights into overcoming therapeutic resistance in RAS-mutated cancers.

Main Methods:

  • Review and synthesis of recent findings on nongenetic resistance mechanisms.
  • Analysis of cell plasticity as a driver of acquired resistance.
  • Focus on pancreatic ductal adenocarcinoma and non-small cell lung cancer models.

Main Results:

  • Nongenetic mechanisms, such as epigenetic alterations and signaling pathway rewiring, contribute significantly to RAS inhibitor resistance.
  • Cell plasticity allows cancer cells to adapt and survive under RAS inhibitor treatment, leading to acquired resistance.
  • These mechanisms are evident in both pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Conclusions:

  • Nongenetic factors and cell plasticity are pivotal in the development of resistance to RAS inhibitors.
  • Targeting these nongenetic mechanisms and understanding cell plasticity are essential for improving treatment strategies.
  • Further research is needed to develop combination therapies that overcome resistance in RAS-driven cancers.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K